Search clinical trials for: Insulins

Total 2781 results

Sanofi

Completed

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy (EDITION AP)

Type 2 Diabetes Mellitus

China, Taiwan, Korea, Republic of
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)

Type 2 Diabetes

Canada
Rush University Medical Center

Terminated

Carbohydrate Consumption as a Factor in Aspart Dosing (CARB)

Diabetes

United States
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Eli Lilly and Company

Completed

Bioequivalence of Two Lispro Formulations

Healthy Volunteers

Singapore
Diabetes Care Center

Unknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Diabetes Mellitus Type 1

United States
Pfizer

Completed

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Diabetes

Japan
Novo Nordisk A/S

Completed

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Healthy | Diabetes

United States
University of New Mexico
Sanofi

Completed

Comparative Trial Between 3 Types of Insulin Infusion Protocols

Hyperglycemia

United States
Eli Lilly and Company

Completed

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Diabetes Mellitus, Type 1

France, Germany, Hungary
Medical University of Warsaw

Completed

Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal

Diabetes Mellitus, Type 1

Poland
LMC Diabetes & Endocrinology Ltd.
Sanofi

Unknown

Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT) (FIT)

Diabetes Mellitus, Type 1

Canada
Eli Lilly and Company

Completed

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Greece, India, Netherlands, Poland, Puerto Rico
Karolinska Institutet

Completed

Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes (SDIS)

Stroke | Renal Failure | Coronary Heart Disease

Sweden
Spectrum Health Hospitals
Helen DeVos Children's Hospital

Completed

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues

Diabetes | Diabetes Mellitus, Type 1

Romania
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Sansum Diabetes Research Institute
Eli Lilly and Company

Completed

Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

Gestational Diabetes Mellitus
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

Diabetes Mellitus

Germany
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial) (RESET-IT)

Type 2 Diabetes

Canada
Gan and Lee Pharmaceuticals, USA

Enrolling by invitation

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects With T2DM

Type 2 Diabetes

China
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Malaysia, Mexico, Turkey, Thailand, Korea, Republic of
Mannkind Corporation

Completed

Afrezza With Basal Combination (ABC)

Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Croatia, Hungary, India
Third Affiliated Hospital, Sun Yat-Sen University
Guangdong Provincial Department of Science and Technology

Unknown

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes (COGFOST)

Diabetes Mellitus, Type 2

China
Sanofi

Completed

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Italy
Rambam Health Care Campus

Completed

Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus

Diabetes Mellitus | Ventricular Dysfunction

Israel
University of Roma La Sapienza

Completed

Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit

Hyperglycemia

Italy
University Hospital, Montpellier

Completed

Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (SHAN)

Type 1 Diabetes

France
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Type 2 Diabetes

United States, Spain, Taiwan, Japan, Poland, Argentina, Hungary, Puerto Rico, Korea, Republic of, Slovakia
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)

Diabetes | Type 1 Diabetes

United States, Taiwan, Japan, Poland, Argentina, Slovakia, Puerto Rico
The Cleveland Clinic
Novo Nordisk A/S

Completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D)

Type 2 Diabetes

United States
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Diasome Pharmaceuticals
Integrium

Completed

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) (ISLE-1)

Type 1 Diabetes Mellitus

United States
University of Colorado, Denver

Completed

Insulin Pump to Multiple Daily Injection Transition Clinical Trial (TRANSITION)

Type 1 Diabetes

United States
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Extended Bolus for Meals in a Closed-loop System

Type 1 Diabetes

United States
Biodel

Completed

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Diabetes Mellitus

United States
Hallym University Medical Center

Completed

Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice (ARISE)

Diabetes Mellitus, Type 2

Malaysia, South Africa, Philippines, Australia, India, Saudi Arabia
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
Novo Nordisk A/S

Completed

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S
HNEC TEST

Completed

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Arkansas Children's Hospital Research Institute

Completed

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy (ktpump)

Diabetes Mellitus

United States
Biodel

Completed

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

Type 2 Diabetes

Germany
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia

3

Subscribe